Lin Cheng1,2,3, Lihua Zhang2,3, Lichen Gao4, Wei Zhang2,3, Xiaoping Chen2,3, Hong-Hao Zhou2,3. 1. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. 2. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China. 3. Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha, Hunan, P. R. China. 4. Department of Pharmacy, Department of Oncology, Cancer Institute, Changsha Central Hospital, Changsha, Hunan, P. R. China.
Abstract
OBJECTIVES: A new method of HLA-B*5801 genotyping was compared with sequence-based typing (SBT) to find an accurate and prompt method in genotyping HLA-B*5801. METHODS: Two groups of patients from allopurinol-induced cutaneous adverse reactions (SCARs) and allopurinol-tolerant were both genotyped with PG5801 kit and SBT method. The genotyping results of HLA-B*5801 were compared between the two groups. RESULTS: The PG5801 detection kit results were 100% (79/79) in agreement with the SBT genotyping results for identifying the HLA-B*5801 (+) patients. No false-positive or false-negative errors were found. The sensitivity, specificity, rate of adherence, positive predictive value (PPV) and negative predictive value (NPV) were 100%. CONCLUSION: The potential fast screening method is an ideal tool to rule out the high-risk allopurinol-induced SCARs patients.
OBJECTIVES: A new method of HLA-B*5801 genotyping was compared with sequence-based typing (SBT) to find an accurate and prompt method in genotyping HLA-B*5801. METHODS: Two groups of patients from allopurinol-induced cutaneous adverse reactions (SCARs) and allopurinol-tolerant were both genotyped with PG5801 kit and SBT method. The genotyping results of HLA-B*5801 were compared between the two groups. RESULTS: The PG5801 detection kit results were 100% (79/79) in agreement with the SBT genotyping results for identifying the HLA-B*5801 (+) patients. No false-positive or false-negative errors were found. The sensitivity, specificity, rate of adherence, positive predictive value (PPV) and negative predictive value (NPV) were 100%. CONCLUSION: The potential fast screening method is an ideal tool to rule out the high-risk allopurinol-induced SCARspatients.
Authors: S H Kardaun; A Sidoroff; L Valeyrie-Allanore; S Halevy; B B Davidovici; M Mockenhaupt; J C Roujeau Journal: Br J Dermatol Date: 2007-03 Impact factor: 9.302
Authors: L Atzori; A L Pinna; L Mantovani; C Ferreli; M Pau; M Mulargia; N Aste Journal: J Eur Acad Dermatol Venereol Date: 2011-10-24 Impact factor: 6.166
Authors: M L S Chiu; M Hu; M H L Ng; C K Yeung; J C-Y Chan; M M Chang; S H Cheng; L Li; B Tomlinson Journal: Br J Dermatol Date: 2012-05-08 Impact factor: 9.302